A tribute to John Mendelsohn: A pioneer in targeted cancer therapy

Rakesh Kumar, Marc Van De Vijver, Giampaolo Tortora, Fortunato Ciardiello, Tzipora Goldkorn, Wilson H. Miller, Larry Norton

Research output: Contribution to journalReview article

Abstract

Cancer scientists and clinicians are mourning the death of one of the most accomplished members of their community: Dr. John Mendelsohn. He was a pioneer in targeted cancer therapy and was instrumental for the discovery and deployment of the first antagonist epidermal growth factor receptor (EGFR) therapeutic antibodies, broadening the concept of targeted EGFR therapy to encompass other receptor tyrosine kinases, such as HER2, and developing blocking antibody-combination therapy with chemotherapies or radiotherapy. Dr. Mendelsohn, who died on January 7, 2019, always led by the strength of his accomplishments and the humility of his character. Above all, he was a well-revered mentor and clinician, who extended compassion and the gift of his time to patients, colleagues, and mentees alike. In tribute to Dr. Mendelsohn, Cancer Research has invited his former mentees and colleagues who were associated with Dr. Mendelsohn for over three decades to reflect on the broad impact of his work. Here, we discuss Dr. Mendelsohn's illustrious career at three elite academic cancer institutions and hospitals in the United States, his acumen to build, grow, and uplift institutions, and train a generation of medical oncologists, physician scientists, and cancer biologists. His profound legacy on targeted therapy and cancer research and treatment continue to prolong and save the lives of cancer patients globally.

Original languageEnglish (US)
Pages (from-to)4315-4323
Number of pages9
JournalCancer Research
Volume79
Issue number17
DOIs
StatePublished - Sep 1 2019

Fingerprint

Neoplasms
Epidermal Growth Factor Receptor
Therapeutics
Cancer Care Facilities
Gift Giving
Mentors
Blocking Antibodies
Grief
Receptor Protein-Tyrosine Kinases
Research
Radiotherapy
Physicians
Drug Therapy
Antibodies
Oncologists

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kumar, R., Van De Vijver, M., Tortora, G., Ciardiello, F., Goldkorn, T., Miller, W. H., & Norton, L. (2019). A tribute to John Mendelsohn: A pioneer in targeted cancer therapy. Cancer Research, 79(17), 4315-4323. https://doi.org/10.1158/0008-5472.CAN-19-0989

A tribute to John Mendelsohn : A pioneer in targeted cancer therapy. / Kumar, Rakesh; Van De Vijver, Marc; Tortora, Giampaolo; Ciardiello, Fortunato; Goldkorn, Tzipora; Miller, Wilson H.; Norton, Larry.

In: Cancer Research, Vol. 79, No. 17, 01.09.2019, p. 4315-4323.

Research output: Contribution to journalReview article

Kumar, R, Van De Vijver, M, Tortora, G, Ciardiello, F, Goldkorn, T, Miller, WH & Norton, L 2019, 'A tribute to John Mendelsohn: A pioneer in targeted cancer therapy', Cancer Research, vol. 79, no. 17, pp. 4315-4323. https://doi.org/10.1158/0008-5472.CAN-19-0989
Kumar R, Van De Vijver M, Tortora G, Ciardiello F, Goldkorn T, Miller WH et al. A tribute to John Mendelsohn: A pioneer in targeted cancer therapy. Cancer Research. 2019 Sep 1;79(17):4315-4323. https://doi.org/10.1158/0008-5472.CAN-19-0989
Kumar, Rakesh ; Van De Vijver, Marc ; Tortora, Giampaolo ; Ciardiello, Fortunato ; Goldkorn, Tzipora ; Miller, Wilson H. ; Norton, Larry. / A tribute to John Mendelsohn : A pioneer in targeted cancer therapy. In: Cancer Research. 2019 ; Vol. 79, No. 17. pp. 4315-4323.
@article{325604cd425b4bac81d715534354480b,
title = "A tribute to John Mendelsohn: A pioneer in targeted cancer therapy",
abstract = "Cancer scientists and clinicians are mourning the death of one of the most accomplished members of their community: Dr. John Mendelsohn. He was a pioneer in targeted cancer therapy and was instrumental for the discovery and deployment of the first antagonist epidermal growth factor receptor (EGFR) therapeutic antibodies, broadening the concept of targeted EGFR therapy to encompass other receptor tyrosine kinases, such as HER2, and developing blocking antibody-combination therapy with chemotherapies or radiotherapy. Dr. Mendelsohn, who died on January 7, 2019, always led by the strength of his accomplishments and the humility of his character. Above all, he was a well-revered mentor and clinician, who extended compassion and the gift of his time to patients, colleagues, and mentees alike. In tribute to Dr. Mendelsohn, Cancer Research has invited his former mentees and colleagues who were associated with Dr. Mendelsohn for over three decades to reflect on the broad impact of his work. Here, we discuss Dr. Mendelsohn's illustrious career at three elite academic cancer institutions and hospitals in the United States, his acumen to build, grow, and uplift institutions, and train a generation of medical oncologists, physician scientists, and cancer biologists. His profound legacy on targeted therapy and cancer research and treatment continue to prolong and save the lives of cancer patients globally.",
author = "Rakesh Kumar and {Van De Vijver}, Marc and Giampaolo Tortora and Fortunato Ciardiello and Tzipora Goldkorn and Miller, {Wilson H.} and Larry Norton",
year = "2019",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-19-0989",
language = "English (US)",
volume = "79",
pages = "4315--4323",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - A tribute to John Mendelsohn

T2 - A pioneer in targeted cancer therapy

AU - Kumar, Rakesh

AU - Van De Vijver, Marc

AU - Tortora, Giampaolo

AU - Ciardiello, Fortunato

AU - Goldkorn, Tzipora

AU - Miller, Wilson H.

AU - Norton, Larry

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Cancer scientists and clinicians are mourning the death of one of the most accomplished members of their community: Dr. John Mendelsohn. He was a pioneer in targeted cancer therapy and was instrumental for the discovery and deployment of the first antagonist epidermal growth factor receptor (EGFR) therapeutic antibodies, broadening the concept of targeted EGFR therapy to encompass other receptor tyrosine kinases, such as HER2, and developing blocking antibody-combination therapy with chemotherapies or radiotherapy. Dr. Mendelsohn, who died on January 7, 2019, always led by the strength of his accomplishments and the humility of his character. Above all, he was a well-revered mentor and clinician, who extended compassion and the gift of his time to patients, colleagues, and mentees alike. In tribute to Dr. Mendelsohn, Cancer Research has invited his former mentees and colleagues who were associated with Dr. Mendelsohn for over three decades to reflect on the broad impact of his work. Here, we discuss Dr. Mendelsohn's illustrious career at three elite academic cancer institutions and hospitals in the United States, his acumen to build, grow, and uplift institutions, and train a generation of medical oncologists, physician scientists, and cancer biologists. His profound legacy on targeted therapy and cancer research and treatment continue to prolong and save the lives of cancer patients globally.

AB - Cancer scientists and clinicians are mourning the death of one of the most accomplished members of their community: Dr. John Mendelsohn. He was a pioneer in targeted cancer therapy and was instrumental for the discovery and deployment of the first antagonist epidermal growth factor receptor (EGFR) therapeutic antibodies, broadening the concept of targeted EGFR therapy to encompass other receptor tyrosine kinases, such as HER2, and developing blocking antibody-combination therapy with chemotherapies or radiotherapy. Dr. Mendelsohn, who died on January 7, 2019, always led by the strength of his accomplishments and the humility of his character. Above all, he was a well-revered mentor and clinician, who extended compassion and the gift of his time to patients, colleagues, and mentees alike. In tribute to Dr. Mendelsohn, Cancer Research has invited his former mentees and colleagues who were associated with Dr. Mendelsohn for over three decades to reflect on the broad impact of his work. Here, we discuss Dr. Mendelsohn's illustrious career at three elite academic cancer institutions and hospitals in the United States, his acumen to build, grow, and uplift institutions, and train a generation of medical oncologists, physician scientists, and cancer biologists. His profound legacy on targeted therapy and cancer research and treatment continue to prolong and save the lives of cancer patients globally.

UR - http://www.scopus.com/inward/record.url?scp=85071786244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071786244&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-19-0989

DO - 10.1158/0008-5472.CAN-19-0989

M3 - Review article

C2 - 31213466

AN - SCOPUS:85071786244

VL - 79

SP - 4315

EP - 4323

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 17

ER -